COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

Panchawagh S, Ravichandran N, Barman B, Nune A, Javaid M, Gracia-Ramos AE, Day J, Joshi M, Kuwana M, Saha S, Pande AR, Caballero-Uribe CV, Velikova T, Parodis I, Knitza J, Kadam E, Tan AL, Shinjo SK, Boro H, Sen P, Day J, Nikiphorou E, Ziade N, Milchert M, Cavagna L, Chen YM, Makol A, Agarwal V, Patel A, Pauling JD, Wincup C, Tehozol EAZ, Serrano JR, La Torre IGD, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Goo PA, Shumnalieva R, Hoff LS, El Kibbi L, Halabi H, Vaidya B, Shaharir SS, Hasan AT, Dey D, Gutiérrez CET, Lilleker JB, Salim B, Gheita T, Distler O, Saavedra MA, Kardes S, Andreoli L, Lini D, Schreiber K, Vince MN, Singh YP, Ranjan R, Jain A, Pandya SC, Pilania RK, Sharma A, M MM, Gupta V, Kavadichanda CG, Patro PS, Ajmani S, Phatak S, Goswami RP, Chowdhury AC, Mathew AJ, Shenoy P, Asranna A, Bommakanti KT, Shukla A, Pande AR, Chandwar K, Ghodke A, Fazal ZZ, Cansu DÜ, Yıldırım R, Gasparyan AY, Del Papa N, Sambataro G, Fabiola A, Govoni M, Parisi S, Bocci EB, Sebastiani GD, Fusaro E, Sebastiani M, Quartuccio L, Franceschini F, Sainaghi PP, Orsolini G, De Angelis R, Danielli MG, Venerito V, Grignaschi S, Giollo A, Alluno A, Ioannone F, Fornaro M, Traboco LS, Wibowo SAK, Loarce-Martos J, Prieto-González S, Gonzalez RA, Yoshida A, Nakashima R, Sato S, Kimura N, Kaneko Y, Gono T, Tomaras S, Proft FN, Holzer MT, Gromova MA, Aharonov O, Griger Z, Hmamouchi I, El bouchti I, Baba Z, Giannini M, Maurier F, Campagne J, Meyer A, Langguth D, Limaye V, Needham M, Srivastav N, Hudson M, Landon-Cardinal O, Zuleta WGR, Arbeláez Á, Cajas J, Silva JAP, Fonseca JE, Zimba O, Bohdana D, Ima-Edomwonyi U, Dedeke I, Airenakho E, Madu NH, Yerima A, Olaosebikan H, A B, Koussougbo OD, Palalane E, So H, Ugarte-Gil MF, Chinchay L, Bernaola JP, Pimentel V, Fathi HM, Mohammed RHA, Harifi G, Fuentes-Silva Y, Cabriza K, Losanto J, Colaman N, Cachafeiro-Vilar A, Bautista GG, Ho EJG, González R, Nunez LS, M CV, Báez JT, Alonzo H, Pastelin CBS, Salinas RG, Obiols AQ, Chávez N, Ordóñez AB, Llerena AR, Sierra-Zorita R, Arrieta D, Hidalgo ER, Saenz R, Escalante M I, Calapaqui W, Quezada I, Arredondo G, Aggarwal R, Agarwal V, Chatterjee T, Gupta L (2024)

Publication Type: Journal article

Publication year: 2024

Journal

Book Volume: 44

Pages Range: 73-80

Journal Issue: 1

DOI: 10.1007/s00296-023-05496-y

Abstract

To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.

Authors with CRIS profile

Involved external institutions

Aga Khan University (AKU) / آغا خان یونیورسٹی‎ Pakistan (PK) Instituto Mexicano del Seguro Social Mexico (MX) Royal Melbourne Hospital (RMH) Australia (AU) Byramjee Jeejeebhoy Government Medical College & Sassoon General Hospital India (IN) Mymensingh Medical College / ময়মনসিংহ মেডিকেল কলেজ Bangladesh (BD) Southport and Ormskirk Hospital NHS Trust United Kingdom (GB) Smt. Kashibai Navale Medical College and General hospital India (IN) Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS) India (IN) LEDTC Clinic India (IN) Universidad del Norte Colombia (CO) Sofia University "St. Kliment Ohridski" / Софийски университет "Св. Климент Охридски" Bulgaria (BG) Karolinska University Hospital / Karolinska Universitetssjukhuset Sweden (SE) King Edward Memorial Hospital and Seth G.S. Medical College / கிங் எட்வர்ட் நினைவு மருத்துவமனை,राजा एड्वर्ड स्मारक रुग्णालय व सेठ गोवर्धनदास सुंदरदास वैद्यकीय महाविद्यालय India (IN) NIHR Leeds Musculoskeletal Biomedical Research Unit (LMBRU) United Kingdom (GB) University of São Paulo / Universidade de São Paulo (USP) Brazil (BR) All India Institute of Medical Sciences India (IN) University of Pittsburgh United States (USA) (US) University of Illinois at Chicago United States (USA) (US) The Royal Wolverhampton NHS Trust / Royal Wolverhampton Hospitals NHS Trust United Kingdom (GB)

How to cite

APA:

Panchawagh, S., Ravichandran, N., Barman, B., Nune, A., Javaid, M., Gracia-Ramos, A.E.,... Gupta, L. (2024). COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group. Rheumatology International, 44(1), 73-80. https://dx.doi.org/10.1007/s00296-023-05496-y

MLA:

Panchawagh, Suhrud, et al. "COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group." Rheumatology International 44.1 (2024): 73-80.

BibTeX: Download